Treatment with secukinumab, an IL-17A blocker for treating psoriasis and ankylosing spondylitis, preceded one case of pemphigus [21] and another case of severe, ulcerative lichenoid mucositis [22]. The gene discussed is IL17A; the disease is psoriasis.